30 APRIL 2025, WEDNESDAY
09.00-10.15 ORAL PRESENTATION SESSION - 10
(COVID-19) SARS-CoV-2-Catatonia syndrome; Does it exist? Longitudinal evidence
Diğdem Göverti1, Elif Poyraz2, Beste Nur Güvendi Melenkiş2, Duygu Nur Tutam3, Serdar Dursun4
-
Show more (Affiliations)
1. Department of Psychiatry, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
2. Department of Pyschiatry, Erenköy Training and Research Hospital for Mental Health and Neurological Disorders, Istanbul, Turkey
3. Department of Psychiatry, Yüksekova State Hospital, Hakkari, Turkey
4. Department of Psychiatry, University of Alberta, Alberta, Canada
DOI: 10.5080/kes27.abs19 Page 40
BACKGROUND AND AIM: Catatonia is a complex neurobehavioral syndrome related with several psychiatric and medical conditions. Dysfunction of cortical-subcortical motor regulation systems, including GABA, dopamine, and glutamate, or increased and sympathetic freezing response may be some of the mechanisms. Neuropsychiatric symptoms due to SARS-CoV-2 (COVID-19) develop as complications, such as anosmia, thrombotic events, cognitive and attention disorders, depression and psychosis. Catatonic conditions occurring secondary to COVID-19 are found in the literature when there is no underlying psychiatric etiology. In this study, we aimed to investigate catatonia retrospectively in the period of 2 years before and after the pandemic.
METHODS (Ethics Committee Approval must be obtained and the number should be specified.) The study has been designed as a restrospective chart review. The data was investigated by three psychiatrists for the period of 2 years before and after the released first COVID-19 case as two groups in 2022. Individuals diagnosed with 'Catatonia' according to DSM-5-TR who applied to the emergency department, outpatient and inpatient clinics of Erenköy Mental Health Hospital Ethics approval was taken by the committee with the number of 186700 in 10/05/2022.
RESULTS: Forty patients were included in the study, consisting of 20 females (50.00%) and 20 males (50.00%). There was no significant difference in pre-(n:21) and post-COVID 19 (n:19) cases according to age, gender, underlying cause, treatment applied in two groups (p<0.05). In addition, symptom diversity of catatonia was not statistically significant in both groups (p<0.05). The difference in severity of catatonia cases in the two periods was not statistically significant according to the Bush-Francis Catatonia scale (p<0.05). DISCUSSION: While cases of catatonic syndrome developing during COVID-19 infection are reported in the literature, there are also patients with 'delayed' or 'excited-induced' catatonia after infection and a patient presenting with catatonia clinic 6 weeks after COVID-19 infection.
27th National Clinical Education Symposium Presentation Abstracts